Results 211 to 220 of about 164,031 (270)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
This cross‐sectional study of 84 general practices found 24.3% had At‐Risk MASH defined by FNI > 0.30, and 4.3% had advanced fibrosis defined by FIB‐4 > 2.67. Diabetes and socio‐economic disadvantage were strong predictors of significant liver disease.
Leon A. Adams   +7 more
wiley   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber   +4 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Pulmonary vasodilator therapy in COPD-associated pulmonary hypertension: A real-world case series of 14 patients confirmed by right heart catheterization. [PDF]

open access: yesRespir Med Case Rep
Vera Ricaurte M   +10 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence

open access: yesBritish Journal of Pharmacology, EarlyView.
Angiotensin II induces vascular inflammation, senescence, extracellular matrix (ECM) degradation and endothelial dysfunction, thus impairing SK+/IK+ channel function and reducing endothelial‐dependent hyperpolarisation (EDH). Metformin activates AMPK, increasing SK+/IK+ channel function and restoring vasorelaxation.
Soroush Mohammadi Jouabadi   +10 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam   +3 more
wiley   +1 more source

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension. [PDF]

open access: yesHeart Fail Rev
Cabada-García MJ   +16 more
europepmc   +1 more source

Cardiometabolic Risk in First Degree Relatives of Women With Polycystic Ovary Syndrome (PCOS)

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Polycystic ovary syndrome (PCOS) is a common multisystem disorder with reproductive, cardiometabolic and psychological implications. Genetic factors play a role in the pathogenesis of PCOS. We sought to investigate the cardiometabolic health of first degree relatives (FDR) of women with PCOS.
Su Jen Chua   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy